Your browser is no longer supported

For the best possible experience using our website we recommend you upgrade to a newer version or another browser.

Your browser appears to have cookies disabled. For the best experience of this website, please enable cookies in your browser

We'll assume we have your consent to use cookies, for example so you won't need to log in each time you visit our site.
Learn more

New prostate drug could delay use of chemo

  • Comment

A new option for the early treatment of prostate cancer has been licensed for use in the UK and other European Union countries.

Abiraterone acetate (Zytiga) is the first drug to be licensed for treating the disease stage after hormones but before chemotherapy.

Its use could, therefore, potentially delay the need for cytotoxic chemotherapy.

Specifically the drug has been licensed for use in conjunction with prednisolone, for the treatment of metastatic castration resistant prostate cancer in men who are asymptomatic, or mildly symptomatic, after failure of androgen deprivation therapy in whom chemotherapy is not yet clinically indicated.

Bruce Turner, nurse practitioner at Homerton University Hospital and Barts Health, welcomed the licensing of the new drug.

He said: “The availability of an additional treatment approach that can be used in the urology clinic is an exciting development for nurses, who have long been at the heart of providing care and administering hormonal treatments for prostate cancer patients as part of the multidisciplinary team.”

  • Comment

Have your say

You must sign in to make a comment

Please remember that the submission of any material is governed by our Terms and Conditions and by submitting material you confirm your agreement to these Terms and Conditions. Links may be included in your comments but HTML is not permitted.

Related Jobs